Bill restores Medicaid protections, brings orphan drugs back to Medicare negotiation

What it does

This bill repeals two provisions from a 2025 reconciliation act: one that tightened Medicaid cost-sharing rules (Section 71120) and another that excluded orphan drugs from Medicare's drug price negotiation program (Section 71203). By repealing these sections, the bill restores the prior Medicaid cost-sharing protections and brings orphan drugs back into Medicare's negotiation scope. The bill also rescinds appropriations tied to the Medicaid cost-sharing changes.

Why we flagged it

The bill's core function is to undo two 2025 cost-control measures that restricted Medicaid beneficiaries' protections and limited Medicare's drug negotiation authority. It is a straightforward restoration of prior policy, not a new regulatory regime.

What the text implies

• Restoring Medicaid cost-sharing protections may increase state Medicaid expenditures if beneficiaries use more services at lower out-of-pocket cost, potentially pressuring state budgets unless federal matching rates adjust.
• Bringing orphan drugs back into Medicare negotiation scope may reduce pharmaceutical revenue from orphan indications, potentially affecting R&D incentives for rare-disease treatments unless other incentive structures (tax credits, exclusivity periods) remain intact.
• The bill does not address whether the prior cost-sharing rules or orphan-drug exclusion were themselves justified by policy rationale; it simply restores the status quo ante, leaving underlying policy debates unresolved.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicaid beneficiaries regain cost-sharing protections that shield them from higher out-of-pocket expenses, and Medicare's ability to negotiate orphan drug prices is restored, potentially lowering costs for seniors. Both changes reduce financial barriers to essential medications for vulnerable populations.

Who stands to gain

• Medicaid beneficiaries (reduced cost-sharing burden)
• Medicare beneficiaries (potential savings from orphan drug price negotiation)

Named in the bill

Medicaid (Title XIX, Social Security Act), Medicare (Title XI, Social Security Act), Section 71120 (Public Law 119–21), Section 71203 (Public Law 119–21), H. Con. Res. 14, Drug Price Negotiation Program

Where it stands

7 cosponsors: 6 Democrats, 1 Independents.

• Jul 24, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 24, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $150,000 in lobbying spend. A filing names 17 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Peter Welch, the sponsor, reported $44,000 in PAC receipts in the 2026 cycle.

• Sun Life Financial (u.s.) Services Company Inc. — $150,000 on 1 filing

Lobbying Disclosure Act filings through Jan 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.